Prognostic value of circulating microRNA-21 in digestive system cancers: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 4, 2014, Pages 873-878

  Ye, Ting Ting ^a   Yang, Yin Long ^a   Liu, Xin Ying ^b   Ji, Qian Qing ^a   Pan, Yi Fei ^a   Xiang, You Qun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Biomarker; Circulating mir 21; Digestive cancer; Meta analysis; Prognosis

Indexed keywords

MICRORNA 21;

ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; DATA EXTRACTION; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; ETHNICITY; FOLLOW UP; GENETIC HETEROGENEITY; HAZARD RATIO; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN EXPRESSION; PUBLICATION; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

EID: 84900432911     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
2. Lee RC, Feinbaum RL and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
3. Madhavan D, Cuk K, Burwinkel B and Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 2013; 4: 116.
4. Shen J, Stass SA and Jiang F. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 2013; 329: 125-136.
5. Komatsu S, Ichikawa D, Takeshita H, Konishi H, Nagata H, Hirajima S, Kawaguchi T, Arita T, Shiozaki A, Fujiwara H, Okamoto K and Otsuji E. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. Expert Opin Biol Ther 2012; 12 Suppl 1: S53-59.
6. Komatsu S, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T, Shiozaki A, Kubota T, Fujiwara H, Okamoto K and Otsuji E. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res 2013; 33: 271-276.
7. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, Ba Y and Zhang CY. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58: 610-618.
8. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR and Goel A. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 2013; 105: 849-859.
9. Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B, Li Y and Sun XF. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumour Biol 2013; 34: 2175-2181.
10. Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez JM and Rodriguez-Montes JA. Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol 2013; 108: 369-373.
11. Song J, Bai Z, Zhang J, Meng H, Cai J, Deng W, Bi J, Ma X and Zhang Z. Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett 2013; 6: 1733-1737.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA and Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
13. Parmar MK, Torri V and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
14. Chen W, Wang H, Chen H, Liu S, Lu H, Kong D, Huang X, Kong Q and Lu Z. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese Population. Eur J Haematol 2014; 92: 407-12.
15. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS and Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675.
16. Ferracin M, Veronese A and Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010; 10: 297-308.
17. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011; 6: e17745.
18. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251: 499-505.
19. Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010; 127: 118-126.
20. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS and Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009; 58: 1375-1381.
21. Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, Ling S, Jiang L, Tian Y and Lin TY. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol 2010; 25: 1674-1680.
22. Wang LG and Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol 2012; 36: e61-67.
23. Krichevsky AM and Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009; 13: 39-53.
24. Yang CH, Yue J, Pfeffer SR, Handorf CR and Pfeffer LM. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 2011; 286: 39172-39178.